高效血浆代谢指纹图谱作为胃癌诊断与预后新工具:一项大规模多中心研究
该大规模多中心研究基于血浆代谢指纹图谱(PMF)构建胃癌诊断与预后模型。回顾性队列1944人来自7个中心,前瞻性队列264人来自牵头中心。诊断模型在回顾性队列发现集和外部验证集的AUC分别为0.862-0.988,21种代谢物组合的AUC分别为0.921-0.971和0.907-0.940;前瞻性队列中NPELDI-MS和UPLC-MS验证的AUC分别为0.855-0.918和0.856-0.916。预后评分系统可有效预测胃癌患者生存。
要点
- 基于NPELDI-MS的血浆代谢指纹图谱具有高通量、良好重现性和有限的中心特异性效应。
- 21种代谢物组合在回顾性队列发现集和验证集的诊断AUC分别为0.921-0.971和0.907-0.940。
- 前瞻性队列中NPELDI-MS和UPLC-MS验证代谢组合的诊断AUC分别为0.855-0.918和0.856-0.916。
核心结论
- 研究开发并验证了胃癌诊断与预后模型,并有助于推进面向疾病的先进代谢分析,包括但不限于胃癌。
研究设计与样本
- 大规模多中心研究,回顾性队列含来自7个中心的1944名参与者,前瞻性队列含来自牵头中心的264名参与者。
- 通过纳米颗粒增强激光解吸/电离-质谱(NPELDI-MS)获取血浆代谢指纹图谱(PMF),在回顾性队列中通过机器学习和Cox回归进行诊断与预后模型的发现和验证。
- 前瞻性队列中采用NPELDI-MS和超高效液相色谱-质谱(UPLC-MS)两种方法验证诊断模型。
主要发现
- 回顾性队列发现集(n=1157,来自5个中心)和独立外部验证集(n=787,来自另外2个中心)中,5种机器学习方法(神经网络、岭回归、lasso回归、支持向量机和随机森林)诊断AUC为0.862-0.988。
- 21种代谢物组合在发现集和验证集的诊断AUC分别为0.921-0.971和0.907-0.940。
- 前瞻性研究(n=264,来自牵头中心)中,NPELDI-MS和UPLC-MS检测验证代谢组合的诊断AUC分别为0.855-0.918和0.856-0.916。
- 在回顾性队列中构建了胃癌预后评分系统,可有效预测胃癌患者生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Metabolic biomarkers are expected to decode the phenotype of gastric cancer (GC) and lead to high-performance blood tests towards GC diagnosis and prognosis. We attempted to develop diagnostic and prognostic models for GC based on plasma metabolic information. DESIGN: We conducted a large-scale, multicentre study comprising 1944 participants from 7 centres in retrospective cohort and 264 participants in prospective cohort. Discovery and verification phases of diagnostic and prognostic models were conducted in retrospective cohort through machine learning and Cox regression of plasma metabolic fingerprints (PMFs) obtained by nanoparticle-enhanced laser desorption/ionisation-mass spectrometry (NPELDI-MS). Furthermore, the developed diagnostic model was validated in prospective cohort by both NPELDI-MS and ultra-performance liquid chromatography-MS (UPLC-MS). RESULTS: We demonstrated the high throughput, desirable reproducibility and limited centre-specific effects of PMFs obtained through NPELDI-MS. In retrospective cohort, we achieved diagnostic performance with areas under curves (AUCs) of 0.862-0.988 in the discovery (n=1157 from 5 centres) and independent external verification dataset (n=787 from another 2 centres), through 5 different machine learning of PMFs, including neural network, ridge regression, lasso regression, support vector machine and random forest. Further, a metabolic panel consisting of 21 metabolites was constructed and identified for GC diagnosis with AUCs of 0.921-0.971 and 0.907-0.940 in the discovery and verification dataset, respectively. In the prospective study (n=264 from lead centre), both NPELDI-MS and UPLC-MS were applied to detect and validate the metabolic panel, and the diagnostic AUCs were 0.855-0.918 and 0.856-0.916, respectively. Moreover, we constructed a prognosis scoring system for GC in retrospective cohort, which can effectively predict the survival of GC patients. CONCLUSION: We developed and validated diagnostic and prognostic models for GC, which also contribute to advanced metabolic analysis towards diseases, including but not limited to GC.
引用
- Xu Z, Huang Y, Hu C, et al. Efficient plasma metabolic fingerprinting as a novel tool for diagnosis and prognosis of gastric cancer: a large-scale, multicentre study. Gut. 2023. PMID: 37460165. doi:10.1136/gutjnl-2023-330045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。